KPTINasdaqPharmaceutical PreparationsFiscal year ends December 31
Karyopharm Therapeutics Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$0.35−0.04 (-11.30%)
Close on Oct 19, 2026
- Market cap
- $10.01K
- P/E (TTM)
- –
- Dividend yield
- –
Karyopharm Therapeutics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Karyopharm Therapeutics | Industry median |
|---|---|---|
| Market Cap | $7.85M | $166.30M |
| Enterprise Value | -$57.25M | $87.12M |
| PS Ratio | 0.05 | 3.60 |
Enterprise value
| Measure | Karyopharm Therapeutics | Industry median |
|---|---|---|
| EV / Sales | -0.39 | 2.43 |
Income (trailing twelve months)
| Measure | Karyopharm Therapeutics | Industry median |
|---|---|---|
| Revenue | $146.62M | $57.94M |
| Operating Income | -$82.35M | -$21.49M |
| Pretax Income | -$224.77M | -$14.72M |
| Net Income | -$224.74M | -$22.46M |
| EBITDA | -$82.35M | -$17.14M |
Margins
| Measure | Karyopharm Therapeutics | Industry median |
|---|---|---|
| Operating Margin | -56.2% | -44.5% |
| Pretax Margin | -153.3% | -13.0% |
| Profit Margin | -153.3% | -39.2% |
| EBITDA Margin | -56.2% | -31.3% |
Returns
| Measure | Karyopharm Therapeutics | Industry median |
|---|---|---|
| Return on Assets (ROA) | -207.9% | -41.0% |
Growth
| Measure | Karyopharm Therapeutics | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 6.81% | 6.01% |
| Revenue Growth (3Y CAGR) | -2.39% | 2.25% |
| Revenue Growth (5Y CAGR) | 6.21% | 6.42% |
Balance sheet
| Measure | Karyopharm Therapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $65.10M | $62.64M |
| Net Cash (Debt) | $65.10M | $15.77M |
| Net Cash Per Share | $2.87 | $0.66 |
| Equity (Book Value) | -$330.17M | $48.61M |
| Book Value Per Share | -$14.56 | $1.36 |
| Tangible Book Value | -$330.17M | $23.01M |
| Working Capital | -$27.86M | $75.09M |
Financial position
| Measure | Karyopharm Therapeutics | Industry median |
|---|---|---|
| Current Ratio | 0.79 | 3.30 |
| Quick Ratio | 0.71 | 2.39 |
| Interest Coverage | -1.67 | -7.12 |
Cash flow (trailing twelve months)
| Measure | Karyopharm Therapeutics | Industry median |
|---|---|---|
| Operating Cash Flow | -$65.35M | -$12.39M |
Efficiency
| Measure | Karyopharm Therapeutics | Industry median |
|---|---|---|
| Asset Turnover | 1.36 | 0.38 |
| Revenue Per Employee | $643.08K | $398.96K |
| Profits Per Employee | -$985.70K | -$705.27K |
| Employee Count | 228 | 74 |
Dividends and yields
| Measure | Karyopharm Therapeutics | Industry median |
|---|---|---|
| Earnings Yield | -2863.7% | -22.8% |
Shares
| Measure | Karyopharm Therapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 22,681,500 | 58,139,000 |
| Shares Change (YoY) | 136.7% | 11.1% |
| Shares Change (QoQ) | 0.60% | 0.54% |
| Float | 21,834,900 | 49,154,900 |
| Shares Held by Insiders | 3.73% | 11.6% |
| Shares Held by Institutions | 96.1% | 59.4% |
Taxes
| Measure | Karyopharm Therapeutics | Industry median |
|---|---|---|
| Income Tax | -$32.00K | $89.00K |
Scores
| Measure | Karyopharm Therapeutics | Industry median |
|---|---|---|
| Altman Z-Score | -24.67 | -0.27 |
| Piotroski F-Score | 3 | 4 |
Calculated by StockData from Karyopharm Therapeutics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.